26 Results for "

autopalmitoylation

" in MedChemExpress (MCE) Product Catalog:
Products (26)

26 Results for "autopalmitoylation" in MCE Product Catalog:

Cat. No.: HY-P5954
Target:  

Calcium Channel

Research Areas:  

Others

PLTX-II is a calcium channel blocker. PLTX-II has a 44-residue peptide containing ten Cys residues and an O-palmitoylated threonine amide at the carboxy-terminus .
loading...
    loading...
Cat. No.: HY-P10381
Target:  

Inhibitory Antibodies

Research Areas:  

Others

palm11-TTDS-PrRP31 is a strong agonist of GPR10 (EC50: 84 pM). palm11-TTDS-PrRP31 has long-lasting anorexigenic effects .
loading...
    loading...
Cat. No.: HY-179559
CAS No.: 2866423-06-3
Target:  

YAP

Research Areas:  

Cancer

OPN-9643 is a covalent inhibitor targeting the central palmitate binding pocket of TEADs with an IC50 of 15 nM, preventing autopalmitoylation and reducing TEAD-driven luciferase activity and canonical TEAD targets, CTGF and CYR61. OPN-9643 can be used for the research of cancer, such as melanoma .
loading...
    loading...
Cat. No.: HY-182539
CAS No.: 1202877-06-2
Target:  

CGRP Receptor

Research Areas:  

Others Neurological Disease

DD04107 is a neuronal exocytosis inhibitor with a rat Syt1-C2B domain binding Kd of 2.4 μM. DD04107 interferes with synaptobrevin-syntaxin-SNAP-25 complex formation and Syt1-SNARE complex interaction to block α-calcitonin gene-related peptide (α-CGRP) exocytotic release from primary sensory neurons. DD04107 blocks inflammatory ion channel recruitment to nociceptor plasma membranes. DD04107 can be used for the research of chronic inflammatory pain, neuropathic pain, osteosarcoma pain, chemotherapy-induced peripheral neuropathy, diabetic neuropathy, inflammatory pain .
loading...
    loading...
Cat. No.: HY-182673
CAS No.: 1119382-90-9
Target:  

YAP

Research Areas:  

Cancer

VT102 is a TEAD1 inhibitor with a human IC50 of 391 nM. VT102 inhibits auto-palmitoylation, attenuates YAP/TEAD1 interaction, reduces expression of TEAD target genes, and inhibits YAP-mediated luciferase reporter activity. VT102 exerts weak cell growth inhibitory activity in cancer cells. VT102 can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-400902R
CAS No.: 2506273-81-8
Research Areas:  

Cancer

VT3989 (Standard) is the analytical standard of VT3989 (HY-400902). This product is intended for research and analytical applications. VT3989 is an orally active pan-TEAD autopalmitoylation inhibitor that modulates the Hippo signaling pathway. VT3989 directly binds to TEAD transcription factors to block their palmitoylation modification, thereby disrupting the formation of YAP/TAZ-TEAD complexes and inhibiting downstream oncogenic transcriptional activity. VT3989 effectively inhibits the growth of NF2-deficient schwannoma and meningioma cells and reverses the Schwann cell phenotype. In addition, VT3989 exerts a synergistic effect when combined with Osimtinib (HY-15772) in EGFR-mutant non-small cell lung cancer models, significantly delaying tumor recurrence and prolonging survival. VT3989 can be used for the research of epithelioid hemangioendothelioma, malignant pleural mesothelioma, type 2 neurofibromatosis and related advanced solid tumors .
loading...
    loading...